RG 6319
Alternative Names: RG-6319Latest Information Update: 10 Jun 2022
At a glance
- Originator Genentech
- Class Antibacterials
- Mechanism of Action Type I signal peptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Urinary tract infections